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Non Steroid Anti-Inflammatory Drugs (NSAIDs) have
been the treatment of choice for mild to moderate
inflammatory pain for more than a century. NSAIDs
block the formation of prostaglandins by inhibiting
cyclooxygenase (COX). Their most common side-effect
is ulceration of the upper gastrointestinal tract. The
development of selective COX-2 inhibitors (coxibs) has
reduced gastrointestinal toxicity significantly, but coxibs
appear to have a significant cardiovascular risk and to
be less effective in neuropathic pain.
Opioids have traditionally been used for severe acute
and cancer chronic pain, while recently their use in the
therapy of chronic non-cancer pain has increased sub-
stantially. Chronic opioid therapy can be an effective
treatment for carefully selected and monitored patients
with chronic non-cancer pain. However, opioids are also
associated with potentially serious harm, including
opioid-related adverse effects and outcomes related to
the abuse potential of opioids.
Many drugs that are used to treat other illnesses can
also be used for the treatment of chronic and neuro-
pathic pain, either alone or in combination with other
analgesics. These drugs include antidepressants, anticon-
vulsants, antimigraine medicines, local anesthetics, corti-
costeroids, muscle relaxants, benzodiazepines,
neuroleptics, cannabinoids, antihistamines, a2a d r e n e r -
gic agonists, stimulants, biphosphonates and calcitonin,
as well as tramadol, which is a weak μ-opioid agonist
that inhibits the reuptake of norepinephrine and seroto-
nin, too.
Recently, novel targets against inflammatory pain with
improved specificity and fewer side-effects are under
investigation, like prostaglandin E synthases, prostaglan-
din receptors, COX-inhibiting nitric oxide donators
(CINODs), downregulation of inflammatory transcrip-
tion factors and cytokines, and downstream effectors of
prostaglandins in the PNS and CNS. New targets against
chronic inflammatory and neuropathic pain include
modulators of nociception and pain transmission, like
NMDA and other glutamate receptors, GBP and vol-
tage-gated Ca2+ channels (VGCC), nicotinic acetylcho-
line receptors, transient receptor potential (TRP)
channels, tetrodotoxin-resistant Na+ channels, inhibitory
glycine and GABA receptors, monoamine receptors,
adenosine receptors, neuropeptide Y receptors, neuro-
tensin receptors, as well as regulators of inflammation,
neuroinflammation and pain, like nerve growth factor
(NGF), matrix metalloproteases, neuropeptide S, sub-
stance P, neuromedin U, somatostatin and other
neuropeptides.
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